Literature DB >> 33396749

An Algorithm for Nonparametric Estimation of a Multivariate Mixing Distribution with Applications to Population Pharmacokinetics.

Walter M Yamada1, Michael N Neely1,2, Jay Bartroff3, David S Bayard1,4, James V Burke5, Mike van Guilder1, Roger W Jelliffe1, Alona Kryshchenko1,6, Robert Leary7, Tatiana Tatarinova8, Alan Schumitzky1,3.   

Abstract

Population pharmacokinetic (PK) modeling has become a cornerstone of drug development and optimal patient dosing. This approach offers great benefits for datasets with sparse sampling, such as in pediatric patients, and can describe between-patient variability. While most current algorithms assume normal or log-normal distributions for PK parameters, we present a mathematically consistent nonparametric maximum likelihood (NPML) method for estimating multivariate mixing distributions without any assumption about the shape of the distribution. This approach can handle distributions with any shape for all PK parameters. It is shown in convexity theory that the NPML estimator is discrete, meaning that it has finite number of points with nonzero probability. In fact, there are at most N points where N is the number of observed subjects. The original infinite NPML problem then becomes the finite dimensional problem of finding the location and probability of the support points. In the simplest case, each point essentially represents the set of PK parameters for one patient. The probability of the points is found by a primal-dual interior-point method; the location of the support points is found by an adaptive grid method. Our method is able to handle high-dimensional and complex multivariate mixture models. An important application is discussed for the problem of population pharmacokinetics and a nontrivial example is treated. Our algorithm has been successfully applied in hundreds of published pharmacometric studies. In addition to population pharmacokinetics, this research also applies to empirical Bayes estimation and many other areas of applied mathematics. Thereby, this approach presents an important addition to the pharmacometric toolbox for drug development and optimal patient dosing.

Entities:  

Keywords:  adaptive grid; high dimensional statistics; mixture distribution; mixture model; nonparametric maximum likelihood; population model; primal-dual interior-point method

Year:  2020        PMID: 33396749      PMCID: PMC7823953          DOI: 10.3390/pharmaceutics13010042

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  21 in total

1.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

2.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Evaluation of the nonparametric estimation method in NONMEM VI.

Authors:  Radojka M Savic; Maria C Kjellsson; Mats O Karlsson
Journal:  Eur J Pharm Sci       Date:  2008-12-30       Impact factor: 4.384

4.  Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹.

Authors:  David S Bayard; Michael Neely
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-12-01       Impact factor: 2.745

5.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12

6.  Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation.

Authors:  Anders Åsberg; Karsten Midtvedt; Mike van Guilder; Elisabet Størset; Sara Bremer; Stein Bergan; Roger Jelliffe; Anders Hartmann; Michael N Neely
Journal:  Transpl Int       Date:  2013-10-15       Impact factor: 3.782

7.  Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.

Authors:  Jürgen B Bulitta; Yuanyuan Jiao; Cornelia B Landersdorfer; Dhruvitkumar S Sutaria; Xun Tao; Eunjeong Shin; Rainer Höhl; Ulrike Holzgrabe; Ulrich Stephan; Fritz Sörgel
Journal:  Pharmaceutics       Date:  2019-07-10       Impact factor: 6.321

8.  Novel Population Pharmacokinetic Model for Linezolid in Critically Ill Patients and Evaluation of the Adequacy of the Current Dosing Recommendation.

Authors:  Amaia Soraluce; Helena Barrasa; Eduardo Asín-Prieto; Jose Ángel Sánchez-Izquierdo; Javier Maynar; Arantxazu Isla; Alicia Rodríguez-Gascón
Journal:  Pharmaceutics       Date:  2020-01-09       Impact factor: 6.321

9.  Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis.

Authors:  George L Drusano; Michael Neely; Michael Van Guilder; Alan Schumitzky; David Brown; Steven Fikes; Charles Peloquin; Arnold Louie
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

10.  Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate.

Authors:  Femke de Velde; Brenda C M de Winter; Michael N Neely; Walter M Yamada; Birgit C P Koch; Stephan Harbarth; Elodie von Dach; Teun van Gelder; Angela Huttner; Johan W Mouton
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

View more
  4 in total

1.  Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.

Authors:  Walter Yamada; Sarah Kim; Mohammed Almoslem; Soyoung Kim; Jenny Myrick; Jocelyn Nole; Brandon Duncanson; Arnold Louie; Charles A Peloquin; Stephan Schmidt; George L Drusano; Michael Neely
Journal:  Antimicrob Agents Chemother       Date:  2022-09-27       Impact factor: 5.938

2.  Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

Authors:  Janak R Wedagedera; Anthonia Afuape; Siri Kalyan Chirumamilla; Hiroshi Momiji; Robert Leary; Mike Dunlavey; Richard Matthews; Khaled Abduljalil; Masoud Jamei; Frederic Y Bois
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-22

3.  Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase.

Authors:  Sarah Kim; Walter M Yamada; Brandon Duncanson; Jocelyn Nole; Stephanie Rogers; Sarah Parker; Meredith Bacci; Nino Mtchedlidze; Charles A Peloquin; Arnold Louie; Stephan Schmidt; George L Drusano; Michael N Neely
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

4.  A pharmacokinetics-based approach to the monitoring of patient adherence to atorvastatin therapy.

Authors:  Gellért Balázs Karvaly; István Karádi; István Vincze; Michael N Neely; Eszter Trojnár; Zoltán Prohászka; Éva Imreh; Barna Vásárhelyi; András Zsáry
Journal:  Pharmacol Res Perspect       Date:  2021-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.